OSE Immunotherapeutics SA (OSE.PA) announced that its licensee, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, has dosed the first patient in the Phase 2 RENGEVITY-201 trial evaluating pegrizeprument to prevent organ rejection in kidney transplant recipients.
OSE Immunotherapeutics Reports First Patient Dosed In Phase 2 RENGEVITY-201 Trial Of Pegrizeprument
